<DOC>
	<DOCNO>NCT02273856</DOCNO>
	<brief_summary>The purpose study document pharmacological treatment strategy use treatment na√Øve previously treat relapsed/refractory iNHL/CLL patient Middle East North African ( MENA ) region . This study also record encounter tumor subtype stage institute pharmacological treatment , well assess clinical outcome treatment .</brief_summary>
	<brief_title>Multicentre Registry Treatments Outcomes Patients With Chronic Lymphocytic Leukaemia ( CLL ) Or Indolent Non Hodgkin 's Lymphoma ( iNHL )</brief_title>
	<detailed_description>Patients follow 30 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Informed consent CLL patient iNHL patient Clinical decision make initiate adapt treatment CLL/iNHL ( `` Need treat '' ) Patient deem unfit enrollment document opinion investigator Watch wait patient Richter 's transformation Patients otherwise eligible ( pharmacological ) intervention Moribund patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukaemia ( CLL )</keyword>
	<keyword>Indolent Non Hodgkin 's Lymphoma ( iNHL )</keyword>
</DOC>